News | March 17, 2009

Edwards Completes Trial Enrollment in Nonsurgical Study Arm for Evaluation of Transcatheter Valve

March 17, 2009 - Edwards Lifesciences Corp. announced it has completed enrollment in the 350-patient nonsurgical study arm of its PARTNER Trial for the Edwards SAPIEN transcatheter aortic heart valve.

"Reaching this milestone is a significant achievement for the subset of patients suffering from severe aortic stenosis who can't tolerate conventional aortic valve replacement. Without a transcatheter heart valve, they have no definitive treatment options for addressing their valve disease," said Craig Smith, M.D., interim surgeon-in-chief and chief of cardiothoracic surgery at NewYork-Presbyterian Hospital/Columbia University Medical Center, the Calvin F. Barber Professor of Surgery at Columbia University College of Physicians and Surgeons, and co-principal investigator for the trial.

The randomized, controlled, multi-center PARTNER (Placement of AoRTic traNscathetER valves) Trial assigns patients into one of two arms: a "nonsurgical" arm, in which the Edwards SAPIEN valve is compared to nonsurgical treatments, and a "surgical" arm, in which the Edwards SAPIEN valve is compared to traditional surgical aortic valve replacement.

The company also announced it plans to provide continued access at PARTNER study sites to the Edwards SAPIEN valve for nonsurgical patients meeting study criteria, pending FDA approval.

Martin B. Leon, M.D., associate director of the Cardiovascular Interventional Therapy (CIVT) Program at NewYork-Presbyterian Hospital and Columbia University Medical Center, professor of medicine at Columbia University College of Physicians and Surgeons, is the co-principal investigator for the U.S. PARTNER Trial. "The dedication of the PARTNER sites in screening and randomizing complex patients is an important achievement. The medical community anxiously awaits results from this landmark trial, which I believe will benchmark the performance of the Edwards SAPIEN valve versus medical management therapies in these high risk patients," said Dr. Leon.

For more information: www.edwards.com

Related Content

Bilateral Artery Use Does Not Improve 10-Year CABG Outcomes
News | Cardiovascular Surgery | September 06, 2018
While it is firmly established that the use of one internal thoracic artery can improve life expectancy in coronary...
Mandatory Public Coronary Artery Bypass Grafting Reporting Associated With Better Patient Outcomes
News | Cardiovascular Surgery | April 30, 2018
Mandatory public reporting of coronary artery bypass grafting (CABG) results in Massachusetts was associated with...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery | September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery | September 08, 2017
September 8, 2017 — ClearFlow Inc.
Videos | Cardiovascular Surgery | July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Intensive Glycemic Control Program Produces Significant Per-Patient Cost Savings for CABG Surgery
News | Cardiovascular Surgery | May 25, 2017
A new study from Emory University observed a near-20 percent reduction in perioperative complications, a 1.2-day...
Risk of Heart Transplant Rejection Reduced by Desensitizing Patient Antibodies
News | Cardiovascular Surgery | May 23, 2017
The risk of heart transplant rejection can be reduced by desensitizing patient antibodies, according to research...
Scientists Show How Cells React to Injury From Open-Heart Surgery
News | Cardiovascular Surgery | May 04, 2017
Cedars-Sinai Heart Institute investigators have learned how cardiac muscle cells react to a certain type of injury that...
ERACS Session Highlights Need for Standardized Best Practices in Cardiac Surgery
News | Cardiovascular Surgery | May 02, 2017
The recently formed group Enhanced Recovery After Cardiac Surgery (ERACS) hosted an organizing session in Boston on...
ClearFlow Receives Frost & Sullivan New Product Innovation Award for PleuraFlow Technology
News | Cardiovascular Surgery | May 01, 2017
ClearFlow Inc. has received the prestigious 2017 Global Frost & Sullivan Award for New Product Innovation. The...
Overlay Init